The following list of Current Clinical IBC Trials Open for New Patient Enrollment was shared by MD Anderson in their Illuminating Hope Newsletter, Issue 31, April 2023.
Neoadjuvant (newly diagnosed before surgery):
None currently – study is on hold for modifications.
SWOG1706 – A phase II randomized trial of olaparib administered concurrently with RT vs. RT alone for inflammatory breast cancer
2016-1096 – A Phase I Study of OTS167PO, a MELK inhibitor, to Evaluate Safety, Tolerability, and Pharmacokinetics in Patients with Advanced Breast Cancer and Dose-Expansion Study in Patients with Triple Negative Breast Cancer.
2021-0327 – A phase 1, first-in-human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor in subjects with HER2 overexpressing solid tumors
2020-0198 – Neratinib and Capmatinib combination in metastatic breast cancer and inflammatory breast cancer patients with abnormal HER2 and c-Met pathway activity as measured by the CELsignia Signaling Analysis Test
2022-0246 – Phase Ib/II Study of EPA-based EphA2 Targeted Therapy for Patients with Metastatic TripleNegative Inflammatory Breast Cancer
2022-0315 – Phase 1b study of EZH1/2 inhibitor valemetostat in combination with trastuzumab deruxtecan in patients with low/null HER2-expressing metastatic breast cancer (NEW)
We are currently actively developing additional clinical trials for patients with newly diagnosed IBC and patients with metastatic disease and will share more details once activated.
Current Clinical IBC Lab Studies:
We currently have 6 open clinical IBC laboratory studies that collect blood and tissue to analyze host and tumor biology and clinical correlations.